SGLT-2 inhibitor cuts need for diuretics in HFpEF, study showsÂ
But a US cardiologist says changing diuretic therapy would be 'unnecessary' in most patients.
Empagliflozin may reduce long-term use of diuretics in older adults with heart failure with preserved ejection fraction, according to international researchers.
Their study results suggested patients treated with the SGLT-2 inhibitor were 43% more likely to permanently discontinue diuretic therapy compared with placebo.Â
Treatment with empagliflozin also improved clinical outcomes without increasing the risk of hyperkalaemia or acute kidney failure regardless of diuretic use, the authors reported in JAMA Cardiology.
In the post-hoc analysis of the EMPEROR-Preserved trial, they used data from 5800 elderly patients to assess the safety and efficacy of empagliflozin (10mg once daily) in combination with background diuretic use.
